Literature DB >> 14985433

The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in vivo.

Anthony R West1, Anthony A Grace.   

Abstract

Nitric oxide (NO)-releasing interneurons are believed to regulate the activity of striatal medium spiny neurons (MSNs) that contain the NO effector enzyme guanylyl cyclase (GC). The involvement of NO-GC signaling in modulating steady-state membrane activity of striatal MSNs was examined using in vivo intracellular recordings in rats. Intrastriatal infusion of a neuronal NO synthase inhibitor or a NO scavenger via reverse microdialysis consistently decreased the amplitude of spontaneously occurring depolarized plateau potentials (up events). Intrastriatal infusion of a NO scavenger also decreased the amplitude of EPSPs evoked during electrical stimulation of the orbital prefrontal cortex. The effect of the NO scavenger on spontaneous up events was partially reversed by coperfusion with a cell-permeable cGMP analog. Intracellular injection of MSNs with a soluble GC inhibitor resulted in large decreases in the following: (1) spontaneous up-event amplitude, (2) responsiveness to depolarizing current, (3) action potential amplitude, and (4) input resistance. These effects were partially reversed by coinjection of cGMP. Conversely, intracellular injection of a phosphodiesterase inhibitor increased MSN neuron membrane excitability. These results indicate that, in the intact animal, the NO signaling pathway exerts a powerful tonic modulatory influence over the membrane activity of striatal MSNs via the activation of GC and stimulation of cGMP production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985433      PMCID: PMC6730403          DOI: 10.1523/JNEUROSCI.4470-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

1.  Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.

Authors:  Stephen Sammut; Kristina E Bray; Anthony R West
Journal:  Psychopharmacology (Berl)       Date:  2007-01-06       Impact factor: 4.530

2.  Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.

Authors:  Sarah Threlfell; Stephen Sammut; Frank S Menniti; Christopher J Schmidt; Anthony R West
Journal:  J Pharmacol Exp Ther       Date:  2008-12-04       Impact factor: 4.030

3.  Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking.

Authors:  Roy S Song; Rosa Tolentino; Eric A Sobie; Susana R Neves-Zaph
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

4.  Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Authors:  Fernando E Padovan-Neto; Stephen Sammut; Shreaya Chakroborty; Alexander M Dec; Sarah Threlfell; Peter W Campbell; Vishnu Mudrakola; John F Harms; Christopher J Schmidt; Anthony R West
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

5.  Distinct roles of GABAergic interneurons in the regulation of striatal output pathways.

Authors:  Aryn H Gittis; Alexandra B Nelson; Myo T Thwin; Jorge J Palop; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

6.  Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission.

Authors:  Sara Arcangeli; Alessandro Tozzi; Michela Tantucci; Cristiano Spaccatini; Antonio de Iure; Cinzia Costa; Massimiliano Di Filippo; Barbara Picconi; Carmen Giampà; Francesca Romana Fusco; Salvatore Amoroso; Paolo Calabresi
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-14       Impact factor: 6.200

7.  Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.

Authors:  Gunasingh J Masilamoni; Subramanian Uthayathas; Gerhard Koenig; Liza Leventhal; Stella M Papa
Journal:  Neuropharmacology       Date:  2016-08-15       Impact factor: 5.250

Review 8.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

9.  Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo.

Authors:  Stephen Sammut; Sarah Threlfell; Anthony R West
Journal:  Neuropharmacology       Date:  2009-12-05       Impact factor: 5.250

10.  Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats.

Authors:  Marian L Logrip; Leandro F Vendruscolo; Joel E Schlosburg; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2014-01-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.